Background: T H 1 cytokines, such as IFNg and TNFa, and potentially innate cytokines, such as IL6, can potentiate the immune response to tumor. Cytokines, such as IL1b, IL8, and IL10, may suppress anticancer immunity. Thus, we prospectively evaluated the association between peripheral-cytokine concentrations and prostate cancer.
Introduction
A better understanding of the etiology of prostate cancer may foster novel prevention and treatment strategies. Chronic inflammation, a causal factor for multiple cancers (1) (2) (3) (4) (5) , has a purported role in the etiology of prostate cancer (6) (7) (8) . Cytokines are important regulators of the immune response, including in cancer.
In the context of cancer, proinflammatory T H 1 cytokines, such as IFNg, TNFa, IL12, and, to some extent, IL6, can drive antitumor immunity (9, 10) . Conversely, T H 2 cytokines, such as IL4, IL5, and IL13, are associated with antibody production and with allergy and asthma (11, 12) . In several cancer models, smoldering T H 2 inflammation has been associated with cancer progression (13) . Finally, innate cytokines, such as IL1b and IL8, have also been associated with cancer progression (14, 15) . Thus, the character of a cancer patient's immune response may be an important prognostic factor for disease-free survival. Whether the circulating cytokine profile influences prostate cancer risk is understudied.
In this study, we prospectively evaluated whether circulating concentrations of IFNg, TNFa, IL12, IL10, IL1b, IL6, and IL8 are associated with prostate cancer incidence in the CLUE II cohort. On the basis of our prior genetic studies in CLUE II (16) , we specifically hypothesized that men with higher circulating IL10 concentrations would have a lower risk of prostate cancer. For the other cytokines, the work was exploratory. Although most cytokines act locally (e.g., at the tissue level), we postulated that broad tendencies, including inherent, toward either a T H 1 or a suppressive profile might be reflected peripherally in circulation. To begin to address this postulation, we also evaluated the cross-sectional association between candidate SNPs and concentrations of inflammatory cytokines.
Materials and Methods

Study population
We conducted a nested case-control study in CLUE II, a community-based cohort study initiated in 1989 in Washington County, MD. A total of 32,898 men and women, one third of the adult population of the county at the time of recruitment, participated. Forty-one percent were men and 98% were white. Men who were free of a cancer diagnosis at baseline (except possibly for nonmelanoma skin cancer) before blood draw were eligible to be a case or control in this analysis. Participants completed a brief medical and exposure history and a food frequency questionnaire at baseline. Blood samples were collected at baseline, processed within 24 hours, and stored at À70 C. Follow-up questionnaires were mailed to study participants in 1996, 1998, and 2000. The Institutional Review Board at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD) approved this study.
Cases and controls
Prostate cancer cases were identified by linkage with the Washington County Cancer Registry, and starting in 1992, additionally by linkage with the Maryland Cancer Registry. Abstracted information included age, date, stage, and Gleason sum at diagnosis. Prostate adenocarcinoma was histologically confirmed after blood draw through December 2002 in 269 men. Prostate cancer cases were classified as clinically organ-confined (T1 or T2) or advanced (T3, T4, Nþ, Mþ, or fatal), and as low (Gleason sum < 7) or high (!7) grade. A participant was eligible to be a control for a case if he was still alive at the date of the case's diagnosis and he did not have a subsequent cancer diagnosis. Controls were individually matched to cases by time since last meal, age and date of blood draw, and race.
Cytokines
Plasma cytokines were measured using the Meso-Scale Discovery (MSD; Gaithersburg, MD) Ultrasensitive Proinflammatory multiplex kit. The MSD multispot array was run according to the manufacturer's protocol with minor modifications. Calibration curves were prepared ranging from 2,500 pg/mL to 0.15 pg/mL. Plates were read using the MS2400 imager (MSD). Samples for each case and matched control were assayed adjacently, but in random order. Each participant sample was assayed in replicate. The percentage of replicates that had a concentration below the lower limit of detection (LOD) for IFNg, TNFa, IL10, IL12, IL1b, IL6, and IL8 were 33.1%, 0.09%, 0.65%, 6.52%, 41.9%, 0.47%, and 0.09%, respectively. Mean replicate concentrations were used in the analysis irrespective of whether one or both values were below the LOD. With exception of IFNg and IL1b, the replicate means for each cytokine were all above the LOD.
To determine assay reliability for the CLUE samples, we calculated the coefficient of variation (CV%) for each man's replicates when both had concentrations above the LOD. The mean CV%s for IFNg, TNFa, IL10, IL12, IL1b, IL6, and IL8 were 14.9%, 3.8%, 9.7%, 10.8%, 19.7%, 8.0%, and 3.4%, respectively. Cytokine concentrations in frozen plasma (heparin) are generally stable (17, 18) .
Covariates
Information collected at baseline included age, race, attained education level, smoking status, use of diabetes medications and prescription and over-the-counter aspirin and other NSAIDs in the past 48 hours, current height and weight, and weight at the age of 21 years. Previously, we genotyped SNPs in genes encoding cytokines (16) .
Statistical analysis
The paired t test (or the Wilcoxon sign rank test) and the McNemar test were used to test for differences between cases and controls in continuous and categorical variables, respectively. Cytokine concentrations were right skewed. We transformed them using the natural logarithm to achieve normality. We estimated geometric mean cytokine concentration among white controls by cytokine genotype. The association between the cytokines and prostate cancer risk overall and by stage and grade was evaluated by quartile of each marker. Quartile cutpoints were determined from the distribution of the cytokine concentrations in the cases and controls combined. For IFNg and IL1b, mean replicate concentrations below the LOD were assigned to the lowest quartile. Conditional logistic regression was used to calculate ORs and 95% confidence intervals (CI) taking into account the matching factors (matched analysis, Model 1), and smoking status and body mass index (BMI; multivariable-adjusted analysis, Model 2). To test for trend, a linear model was fit using the median concentration of each cytokine quartile. Stratified analyses were conducted for age (!65 vs. 65 years; median) and BMI (<25 vs. !25 kg/m 2 ) using unconditional logistic regression adjusting for matching factors. Interaction terms were tested using the Wald test.
Results
Baseline characteristics
Mean baseline age was 64 years and 2.2% of participants were African American (Table 1) . Cases and controls did not differ on family history of prostate cancer, attained education, marital status, BMI, smoking status, or use of aspirin or other NSAIDs. Cases were less likely to use diabetes medications than controls. Mean age at diagnosis was 70 years, 22% had advanced disease, and 31% had Gleason sum !7 disease. Mean time between blood draw and diagnosis was 5.5 AE 3.1 years.
Baseline plasma cytokine concentrations by variation in genes encoding cytokines
Although cytokines typically act locally, we postulated that the tendency, including genetic, to have a particular usual cytokine profile might be reflected in circulation. However, geometric mean cytokine concentrations did not differ by cytokine genotype in the white controls ( Table 2) .
Baseline plasma cytokine concentrations in prostate cancer cases and controls
Geometric mean concentrations of IFNg and TNFa were lower in cases than controls (Table 3 ). There was no statistically significant difference in IL6, IL10, IL12p70, IL1b, or IL8 concentrations between cases and controls. The magnitude of the inverse associations for IFNg and TNFa was generally the same as overall after excluding cases diagnosed within 2 (N ¼ 220, 82%) or 5 years (N ¼ 126, 47%) of blood draw (Supplementary Table S1 ). The associations between the T H 1 cytokines and prostate cancer risk did not seem to be modified by age or obesity (all P interaction ! 0.10).
Association of the anti-inflammatory cytokine IL10 with prostate cancer risk IL10 concentration was not associated with prostate cancer risk either in the matched-or multivariable-adjusted analysis (Table 4) . Furthermore, IL10 concentration was not clearly associated with stage or grade (data not shown). The association between IL10 and prostate cancer risk was similarly null after excluding cases diagnosed within 2 or 5 years of blood draw (Supplementary Table  S1 Table S1 ). Higher IL6 concentration was inversely associated with advanced (matched OR, 0.29; 95% CI, 0.09-0.93; P trend ¼ 0.02) and high-grade (matched OR, 0.20; 95% CI, 0.06-0.67; P trend ¼ 0.003) disease, but not clinically organ-confined or low-grade disease (data not shown).
Although not statistically significant, IL1b was possibly inversely associated with prostate cancer risk, including after excluding cases diagnosed within 2 years (matched OR, 0.70; 95% CI, 0.42-01.14; P trend ¼ 0.11) and 5 years (matched OR, 0.68; 95% CI, 0.41-1.12; P trend ¼ 0.10) of blood draw, and with high-grade disease (OR, 0.51; 95% CI, 0.21-1.23; P trend ¼ 0.13). IL8 concentration was not associated with prostate cancer risk or by stage or grade. Age and obesity did not modify the associations of IL6, IL1b, or IL8 with prostate cancer risk (all P interaction ! 0.11).
Discussion
In this prospective study, circulating cytokine concentrations indicative of a T H 1 type immune response, IFNg and TNFa, were inversely associated with prostate cancer risk. Higher TNFa concentration was associated with a lower risk of high-grade disease. IL6, a cytokine indicative of an innate immune response, and which has been shown to be associated with antitumor T cells in melanoma (19) , also was inversely associated with prostate cancer risk, especially advanced and high-grade disease. IL1b was also possibly inversely associated with prostate cancer risk. The other cytokines, including IL10, were not associated with risk. However, in normal weight, but not overweight/obese men, higher concentration of IL10, a suppressive, anti-inflammatory cytokine, was inversely associated with prostate cancer risk.
Our results support the hypothesis that T H 1 cytokines, including IFNg and TNFa, may function to prevent tumor development. T H 1-type cytokines contribute to inflammatory reactions essential for effective responses against tumor cells (20) . Animal models show that T H 1-type cytokines may serve a protective role against cancer (21) . Kaplan and colleagues demonstrated that endogenously produced IFNg in mice models formed the basis of a tumor surveillance system that controlled the development of tumors that were chemically induced and those that occurred spontaneously (21) . In the study, IFNg receptor-deficient mice developed chemically induced tumors more often and more quickly than wild-type mice. Very few epidemiologic studies have addressed this hypothesis for cancer in humans by measuring circulating T H 1 cytokine levels. A nested case-control study of 270 endometrial cancer cases and 518 matched controls reported that endometrial cancer risk was significantly higher in patients with higher prediagnostic TNFa concentration (22) . The direction of this association is opposite from what we observed for prostate cancer. To our knowledge, no epidemiology study has evaluated the association between prediagnostic concentration of IFNg or TNFa and prostate cancer. We had expected that IL10 would be inversely associated with prostate cancer risk because of its anti-inflammatory actions and because we had previously observed that SNPs in the IL10 promoter that led to greater IL10 production were inversely associated with prostate cancer in CLUE II (16) . IL10 can affect the pathogenesis of prostate cancer by directly inhibiting production of proinflammatory cytokines, such as IL6, TNFa, IL8, or by indirectly inhibiting tumor invasion and metastasis (23, 24) . Men with higher BMI had a higher IL10 level, a Taking into account the matching factors, time since last meal, age and date of blood draw, and race, and adjusting for smoking status and BMI.
finding that is consistent with previous studies (25) . In overweight and obese men, higher IL10 concentration was associated with greater prostate cancer risk, which may signify overproduction of IL10 due to greater adiposity; this may not, however, reflect the inter-prostatic environment. In normal weight men, higher IL10 concentration was inversely associated with prostate cancer. Elevated IL10 level in normal weight men may be indicative of inflammatory stimuli from sources unrelated to adiposity. In normal weight men, prediagnostic circulating IL10 concentration may signify anti-inflammatory processes occurring at the prostate. These anti-inflammatory processes may serve an antitumorigenic role, resulting in lower future prostate cancer risk.
We also noted an inverse association and a possible inverse association for two of the innate immune response cytokines. For IL6, the inverse association was present, in particular, for advanced and for high-grade disease. Our results differ from those in the Physician's Health Study, which were null (26) . IL6 seems to have divergent roles in early stage (i.e., prediagnostic) and late stage (i.e., prevalent prostate cancer). It is well established that patients with prostate cancer have elevated IL6 concentrations (8, 27) , which may serve as a marker for advanced disease, and may mediate morbidity in these patients (27) . Like many cytokines, IL6 is markedly elevated in obese people but in normal weight people, elevated concentrations may signify inflammatory stimuli from sources unrelated to adiposity (26, 28) . Obesity did not modify the IL6 association in our study. In our study, IL1b seemed to be inversely associated with prostate cancer, although not statistically significant. To our knowledge, no studies have reported an association between prediagnostic levels of IL1b and prostate cancer incidence.
Although most cytokines act locally at the tissue level, we postulated that broad tendencies toward either a proinflammatory or suppressive profile, including inherent, might be reflected peripherally in circulation. To examine this hypothesis, we cross-sectionally evaluated the association between SNPs in genes encoding cytokines and circulating cytokine concentrations. The SNPs were selected because they were known or suspected to influence the production or function of the cytokines or were previously associated with other cancers (16) . However, concentrations did not differ across genotype in the controls. A possible explanation includes that we measured cytokine concentrations only at one point in time, which may not be reflective of the usual blood concentrations. Results from other human studies reporting a potential association between these SNPs and cytokine concentration are conflicting (29) (30) (31) (32) (33) .
Several factors should be considered when interpreting our findings. This is the first study, to our knowledge, to evaluate the association between prediagnostic cytokine profile and prostate cancer incidence. Important strengths of this study include a well-established community-based cohort with comprehensive outcome ascertainment. The cytokines were measured using an assay with relatively high sensitivity and precision. Degradation of the cytokines in stored plasma is unlikely to explain the results as cases and control were stored for the same length of time and were handled in the same manner to preserve comparisons. We were able to explore the possible influence of undiagnosed cancer on the findings; none was found.
There are some limitations to the study as well. The relatively small sample size limited the ability to conduct extensive subgroup analyses, especially for advanced prostate cancer. Inflammatory cytokines can be elevated for reasons unrelated to cancer. Noncancer illnesses that can elevate cytokine concentration may cause an attenuation of the association between inflammatory cytokines and prostate cancer incidence. Also, the CV%s of IFNg (14.9%) and IL1b (19.7%) were higher than for the other cytokines. Imprecision of their measurement may have attenuated their associations with prostate cancer. In addition, the study population was largely white, which precluded our ability to determine whether the findings are generalizable to other racial/ ethnic groups.
In summary, we found that men with a prediagnostic circulating cytokine profile consistent with a T H 1 immune response and also some cytokines involved in the innate immune response may have a lower future risk of prostate cancer, including aggressive disease. Whether circulating cytokine profile reflects (i) the intraprostatic immune environment in benign tissue that protects against the development of prostate cancer, (ii) the immune milieu in response to a yet undetected prostate adenocarcinoma that inhibits its growth and thus detectability, and/or (iii) a systemic immune profile that mediates the influence of modifiable factors on prostate cancer risk, warrants additional study. The IL10-obesity interaction also warrants further study. Identifying specific inflammatory cytokines that are associated with prostate cancer incidence may lead to improved prostate cancer prevention and treatment strategies.
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